{"id":"78ad3f318474","type":"article","url":"https://hartvaat.nl/2026/09/09/tolvaptan-bij-hartfalen-conceptueel-kader-voor-gerichte-decongestie/","title":"Tolvaptan bij hartfalen: conceptueel kader voor gerichte decongestie","title_en":"Tolvaptan in heart failure: Contemporary evidence and a framework for precision decongestion.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Heart failure reviews","doi":"10.1007/s10741-026-10677-5","source_url":"https://doi.org/10.1007/s10741-026-10677-5","authors":["Teruhiko Imamura"],"significance":5,"published":"2026-09-17","source_date":"2026-09-09","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"This review evaluates contemporary evidence for tolvaptan, a vasopressin V2 receptor antagonist, in managing congestion among patients with heart failure. While the drug reliably increases urine output and reduces body weight in the short term, it has not demonstrated a reduction in mortality or heart failure hospitalizations. The authors propose a two-stage selection framework utilizing pretreatment and early-response markers, such as urine osmolality, to identify patients most likely to benefit. Clinically, tolvaptan should be viewed as a monitored adjunct for carefully selected individuals rather than a routine or prognostic therapy.","created":"2026-09-10T01:09:17Z","updated":"2026-09-10T01:09:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze review belicht het huidige bewijs voor tolvaptan, een V2-receptorantagonist, bij de behandeling van congestie bij hartfalenpatiënten. Hoewel het middel kortdurend de urineproductie verhoogt en het lichaamsgewicht verlaagt, ontbreekt een bewezen effect op mortaliteit of heropnames voor hartfalen. De auteurs stellen een tweestapskader voor met behulp van biomarkers zoals urine-osmolaliteit om patiënten te selecteren die het meest baat hebben bij deze therapie. Tolvaptan kan zo als gemonitorde adjunct worden ingezet bij geselecteerde patiënten, maar wordt niet aanbevolen als routinematige of prognostisch verbeterende behandeling.","abstract_original":"Congestion remains a major therapeutic target in heart failure (HF), despite advances in guideline-directed medical therapy. Tolvaptan, a selective vasopressin V2 receptor antagonist, promotes electrolyte-sparing free-water excretion and therefore offers a mechanistically distinct approach to decongestion. Randomized trials have generally shown short-term increases in urine output and reductions in body weight, whereas effects on dyspnea and other congestion-related symptoms have been variable; importantly, no reduction in mortality or HF hospitalization has been established. This evidence has led to divergent clinical positioning: tolvaptan is approved in Japan for fluid retention inadequately controlled by other diuretics, whereas the United States and Europe do not approve it for HF congestion. This review critically summarizes the pharmacology, clinical evidence, and regional regulatory context of tolvaptan in HF. It then presents a conceptual two-stage framework incorporating potential pretreatment and early-response markers to inform patient selection, with particular attention to urine osmolality and emerging pathway-based biomarkers. The complementary roles of oral and intravenous formulations and evidence in selected clinical settings are also discussed. Current data support tolvaptan as a monitored adjunct for selected patients, not as routine therapy or a treatment with established prognostic benefit."}